摘要
细胞治疗作为缺血性心脏病心肌修复的创新策略，通过干细胞、祖细胞及基因编辑技术促进心肌再生与血管新生。目前，间充质干细胞、心脏祖细胞及诱导多能干细胞等已在临床试验中展现出改善心功能、减少纤维化的潜力，但其疗效仍受限于细胞存活率、移植效率及标准化制备等问题。转化医学研究聚焦于优化细胞递送系统、生物材料支架及靶向调控微环境，并结合单细胞测序、类器官模型等新技术阐明作用机制。未来需通过多学科交叉推动精准化治疗体系建立，加速基础研究向临床应用的转化。
关键词： 缺血性心脏病；细胞治疗；心肌修复；转化医学；再生医学
Abstract
Cell therapy, as an innovative strategy for myocardial repair of ischemic heart disease, promotes myocardial regeneration and angiogenesis through stem cells, progenitor cells and gene editing technology. At present, mesenchymal stem cells, cardiac progenitor cells and induced pluripotent stem cells have shown the potential to improve cardiac function and reduce fibrosis in clinical trials, but their efficacy is still limited by problems such as cell survival rate, transplantation efficiency and standardized preparation. Translational medicine research focuses on optimizing cell delivery systems, biomaterial scaffolds and targeted regulation of microenvironments, and combines new technologies such as single-cell sequencing and organoid models to clarify the mechanism of action. In the future, it is necessary to promote the establishment of a precision treatment system through multidisciplinary cross-border and accelerate the transformation of basic research to clinical application.
Key words： Ischemic heart disease; Cell therapy; Myocardial repair; Translational medicine; Regenerative medicine
参考文献 References
[1] Razeghian-Jahromi, Iman, et al. "Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy." Stem Cell Research & Therapy 12.1 (2021): 361.
[2] Bolli, Roberto, et al. "Cell therapy in patients with heart failure: a comprehensive review and emerging concepts." Cardiovascular Research 118.4 (2022): 951-976.
[3] Bolli, Roberto, et al. "A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial." European journal of heart failure 23.4 (2021): 661-674.
[4] Zhang, Zhan, et al. "Reactive oxygen species scavenging nanomedicine for the treatment of ischemic heart disease." Advanced Materials 34.35 (2022): 2202169.
[5] Zhou, Yan, et al. "The role of the VEGF family in coronary heart disease." Frontiers in cardiovascular medicine 8 (2021): 738325.
[6] Stone, Peter H., Peter Libby, and William E. Boden. "Fundamental pathobiology of coronary atherosclerosis and clinical implications for chronic ischemic heart disease management—the plaque hypothesis: a narrative review." JAMA cardiology 8.2 (2023): 192-201.
[7] Chang, Xing, et al. "Therapeutic strategies in ischemic cardiomyopathy: Focus on mitochondrial quality surveillance." EBioMedicine 84 (2022).
[8] Assmus, Birgit, et al. "Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A-and TET2-driver gene mutations." European heart journal 42.3 (2021): 257-265.
[9] Chang, Xing, et al. "Molecular mechanisms of mitochondrial quality control in ischemic cardiomyopathy." International journal of biological sciences 19.2 (2023): 426.
[10] Mazidi, Mohsen, et al. "Plasma proteomics to identify drug targets for ischemic heart disease." Journal of the American College of Cardiology 82.20 (2023): 1906-1920.
[11] Shaya, Gabriel E., et al. "Coronary heart disease risk: low-density lipoprotein and beyond." Trends in cardiovascular medicine 32.4 (2022): 181-194.
[12] 刘东月,王宪云,王乐,等.间充质干细胞外泌体移植治疗缺血性心脏病[J].中国组织工程研究, 2023, 27(15):8.
[13] 荆宇澄、王乐、王宪云、魏梅、李敏、吉立双、马芳芳、刘刚、郑明奇.脐带间充质干细胞移植治疗缺血性心脏病患者3年随访[J].中国组织工程研究, 2021, 25(1):7.
[14] 刘东月,王宪云,王 乐,et al.间充质干细胞外泌体移植治疗缺血性心脏病[J].Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu, 2023, 27(15).
[15] 杨继涛.骨髓干细胞移植治疗在缺血性心脏病治疗中的疗效分析[J].饮食保健, 2022(22):29-32.
[16] 齐芳.新方法治疗缺血性心脏病取得临床进展[J].老同志之友, 2021(001):000.
[17] 张桂欢,田海.胚胎干细胞移植治疗缺血性心脏病研究的进展[J].心血管康复医学杂志, 2021.
[18] 谢晓烨,李苏雷,王小宁,等.细胞生物治疗在缺血性心脏病的应用研究进展[J].中华保健医学杂志, 2021, 23(2):4.